{"id":"standard-of-care-ist","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Liver enzyme elevations"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IST works by reducing the number of immune cells that attack the protective covering of nerves in the central nervous system, thereby slowing the progression of multiple sclerosis. This is achieved through the depletion of autoreactive T and B lymphocytes. IST has been shown to reduce the frequency of relapses and slow disease progression in patients with relapsing forms of multiple sclerosis.","oneSentence":"IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:14.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"},{"name":"Active secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06962800","phase":"PHASE3","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Biogen","startDate":"2025-05-22","conditions":"Primary Membranous Nephropathy","enrollment":180},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT05581160","phase":"NA","title":"Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2022-07-11","conditions":"Sexually Transmitted Infections (Not HIV or Hepatitis), Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection","enrollment":332}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard of Care IST","genericName":"Standard of Care IST","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis. Used for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}